Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice
Authors:
- 17 February 2022
- journal article
- review article
- Published by Springer Nature in Neurological Sciences
- Vol. 43 (4) , 2339-2361
Abstract
Neurological, immune-related adverse events (n-irAE) due to immune checkpoint inhibitors (ICI) represent a growing clinical problem in neuro-oncology practice. Although rare, the frequency of n-irAEs will increase as ICI use becomes more common. Central and peripheral nervous systems may be involved, and multiple n-irAEs like myositis, myasthenia gravis, and myocarditis can arise in the same patient. Prompt recognition, initial ICI discontinuation, and treatment with immunosuppressive therapy comprise key aspects of managing these potentially fatal neurological complications. Severe and/or treatment-refractory n-irAEs may occur and require individualized care. In the same vein, a possible reintroduction of ICI after a n-irAE represents an additional challenge in clinical practice. An approach by experienced neurologists involved in highly subspecialized, multidisciplinary care teams is, therefore, of major importance in managing these cases. The present study updates current knowledge regarding presentation forms, diagnostic workflows, outcomes, and general management of n-irAEs. With the aim to guide neurologists in decision-making processes during such scenarios, the study further reviews available data on ICI reintroduction safety in patients with prior n-irAEs.Keywords
Funding Information
- Instituto de Salud Carlos III (PI20/00283)
This publication has 148 references indexed in Scilit:
- Myasthenia gravis exacerbation associated with pembrolizumabMuscle & Nerve, 2016
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune DisordersJAMA Oncology, 2016
- The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in MelanomaClinical Therapeutics, 2015
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanomaMultiple Sclerosis Journal, 2014
- Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking AntibodyScience Translational Medicine, 2014
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Immune mediated neurologic dysfunction as a paraneoplastic syndrome in renal cell carcinomaJournal of Neuro-Oncology, 2008
- Lifetime course of myasthenia gravisMuscle & Nerve, 2007
- Antibody to acetylcholine receptor in myasthenia gravisNeurology, 1976